GENELUX CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
GENELUX CORPORATION (GNLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 14.37 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2026-08-13
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-06-30 was 7.49K shares.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-03-31 was 6.88K shares, a 83.49% decline year-over-year.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-12-31 was 0.00 shares.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-09-30 was 15.13K shares.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2025 was 46.36K shares, a 254.53% increase from fiscal 2024.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2024 was 13.08K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 7.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 14.37K shares 10-Q · filed 2026-08-13 | 14.37K shares derived: sum of 3 quarters · filed 2026-08-13 | 29.49K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 6.88K shares 10-Q · filed 2026-05-07 | 6.88K shares derived: sum of 2 quarters · filed 2026-05-07 | 22.00K shares derived: sum of 3 quarters · filed 2026-05-07 | 11.59K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 15.13K shares derived: sum of 2 quarters · filed 2026-03-19 | 4.71K shares derived: sum of 3 quarters · filed 2026-03-19 | 46.36K shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 15.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 4.71K shares derived: sum of 2 quarters · filed 2025-11-05 | 46.36K shares 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -10.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 31.24K shares 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | 41.65K shares 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | 13.08K shares 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |